171 related articles for article (PubMed ID: 31151671)
1. Pyoderma Gangrenosum With Ulcerative Colitis Successfully Treated With Ustekinumab.
Piqueras-García J; Sahuquillo-Torralba AJ; Torres-Navarro I; Botella-Estrada R
Actas Dermosifiliogr (Engl Ed); 2019 Nov; 110(9):776-778. PubMed ID: 31151671
[No Abstract] [Full Text] [Related]
2. Refractory Pyoderma Gangrenosum in a Patient With Crohn's Disease: Complete Response to Ustekinumab.
Nunes G; Patita M; Fernandes V
J Crohns Colitis; 2019 May; 13(6):812-813. PubMed ID: 30535292
[No Abstract] [Full Text] [Related]
3. Treatment of severe recalcitrant pyoderma gangrenosum with ustekinumab.
Low ZM; Mar A
Australas J Dermatol; 2018 May; 59(2):131-134. PubMed ID: 29205260
[TBL] [Abstract][Full Text] [Related]
4. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
5. Ustekinumab treatment for neutrophilic dermatoses associated with Crohn's disease: A multicenter retrospective study.
de Risi-Pugliese T; Seksik P; Bouaziz JD; Chasset F; Moguelet P; Gornet JM; Bourrier A; Amiot A; Beaugerie L; Francès C; Guégan S;
J Am Acad Dermatol; 2019 Mar; 80(3):781-784. PubMed ID: 30003991
[No Abstract] [Full Text] [Related]
6. Pyoderma gangrenosum solved by ustekinumab therapy.
López González J; Lázaro Sáez M; Moreno Moraleda I; Hernández Martínez Á
Gastroenterol Hepatol; 2021 Apr; 44(4):299-300. PubMed ID: 33069432
[No Abstract] [Full Text] [Related]
7. Coexistence of pyoderma gangrenosum and Sweet's syndrome in a patient with ulcerative colitis.
Castro-Fernández M; Sánchez-Muñoz D; Ruíz-Granados E; Merchante N; Corzo J
Am J Gastroenterol; 2007 Dec; 102(12):2865-6. PubMed ID: 18042124
[No Abstract] [Full Text] [Related]
8. Pyoderma gangrenosum associated with ulcerative colitis: response to infliximab.
López San Román A; Bermejo F; Aldanondo I; Carrera E; Boixeda D; Muñoz Zato E
Rev Esp Enferm Dig; 2004 Jun; 96(6):420-2; 422-4. PubMed ID: 15230672
[TBL] [Abstract][Full Text] [Related]
9. Severe recalcitrant pyoderma gangrenosum treated with infliximab.
Kaur MR; Lewis HM
Br J Dermatol; 2005 Sep; 153(3):689-91. PubMed ID: 16120178
[No Abstract] [Full Text] [Related]
10. Ustekinumab in a patient with pyoderma gangrenosum and refractory Crohn's disease.
García Cámara P; Zubiri Ara ML; García López S
Med Clin (Barc); 2019 Oct; 153(8):e35-e36. PubMed ID: 30795905
[No Abstract] [Full Text] [Related]
11. Successful treatment with ustekinumab and vacuum-assisted closure therapy in recalcitrant myelodysplastic syndrome-associated pyoderma gangrenosum: case report and literature review.
Nieto D; Sendagorta E; Rueda JM; Herranz P
Clin Exp Dermatol; 2019 Jan; 44(1):116-119. PubMed ID: 29851121
[No Abstract] [Full Text] [Related]
12. Pyoderma gangrenosum arising during treatment of psoriasis with adalimumab: Effectiveness of ustekinumab.
Benzaquen M; Monnier J; Beaussault Y; Rouby F; Berbis P
Australas J Dermatol; 2017 Nov; 58(4):e270-e271. PubMed ID: 28660635
[No Abstract] [Full Text] [Related]
13. Infliximab for the treatment of disseminated pyoderma gangrenosum associated with ulcerative colitis. Case report and literature review.
Juillerat P; Christen-Zäch S; Troillet FX; Gallot-Lavallée S; Pannizzon RG; Michetti P
Dermatology; 2007; 215(3):245-51. PubMed ID: 17823524
[TBL] [Abstract][Full Text] [Related]
14. [What is your diagnosis? Pyoderma gangrenosum].
Wieler B; Vorburger D; Lindenmann N
Praxis (Bern 1994); 2009 Dec; 98(25):1497-8. PubMed ID: 20013685
[No Abstract] [Full Text] [Related]
15. Peripheral regional aseptic neutrophilic lymphadenopathy associated with pyoderma gangrenosum.
Al-Niaimi F; Cox NH
Br J Dermatol; 2009 Nov; 161(5):1206-7. PubMed ID: 19678821
[No Abstract] [Full Text] [Related]
16. Pyoderma gangrenosum complicating ulcerative colitis: Successful treatment with methylprednisolone pulse therapy and cyclosporine.
Futami H; Kodaira M; Furuta T; Hanai H; Kaneko E
J Gastroenterol; 1998 Jun; 33(3):408-11. PubMed ID: 9658322
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment of refractory pyoderma gangrenosum with ustekinumab only after excision of renal cell carcinoma.
Cosgarea I; Lovric Z; Körber A; Dissemond J
Int Wound J; 2016 Oct; 13(5):1041-2. PubMed ID: 25294697
[No Abstract] [Full Text] [Related]
18. Systemic pyoderma gangrenosum responding to infliximab and adalimumab.
Hubbard VG; Friedmann AC; Goldsmith P
Br J Dermatol; 2005 May; 152(5):1059-61. PubMed ID: 15888172
[TBL] [Abstract][Full Text] [Related]
19. Ustekinumab as adjuvant treatment for all pyoderma gangrenosum subtypes.
Westerdahl JS; Nusbaum KB; Chung CG; Kaffenberger BH; Ortega-Loayza AG
J Dermatolog Treat; 2022 Jun; 33(4):2386-2390. PubMed ID: 34057010
[No Abstract] [Full Text] [Related]
20. Successful treatment with infliximab of refractory pyoderma gangrenosum in 2 patients with inflammatory bowel diseases.
Cocco A; Angelucci E; Viscido A; Caprilli R
Inflamm Bowel Dis; 2007 Oct; 13(10):1317-9. PubMed ID: 17508417
[No Abstract] [Full Text] [Related]
[Next] [New Search]
